The I-SPY2 trial tested a TLR9 agonist (SD-101) combined with the anti-PD-1 pembrolizumab in the treatment of HER2-negative BC to investigate this novel anti-tumor and immunotherapeutic strategy [126]. This evidence concerns the gene ERBB2 and breast cancer.